Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Dateline City:
KENILWORTH, N.J., and NEW YORK, N.Y.New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary EndpointsKENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.Language:
Englishread more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Janumet | Januvia | Merck | Metformin | Partnerships | Pfizer | Pharmaceuticals | SGLT2 Inhibitors | Study